Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06263726 · 1 trial · 1 indication
Changes from baseline on Draize toxicity assessment score.
Quantitative changes in ECG intervals.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 Experimental Arm | EXPERIMENTAL | - |
| Cohort 2 Experimental Arm | EXPERIMENTAL | - |
| Cohort 3 Experimental Arm | EXPERIMENTAL | - |
| Cohort 3 Placebo Arm | PLACEBO_COMPARATOR | - |
| Cohort 4 Experimental Arm | EXPERIMENTAL | - |
| Cohort 4 Placebo Arm | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-06263726 | DRUG | Subjects will receive dose strength of 2% PF-06263276 (1.14 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back. |
| Placebo | DRUG | Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back. |
Inclusion Criteria: * Healthy male and/or female subjects of non-childbearing potential between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse ...
PF-06263726 is an investigational small molecule developed by Pfizer, Inc. (ticker PFE). It has been studied in a Phase 1 clinical trial conducted in healthy adult volunteers in Belgium. The specific disease or condition it is intended to treat has not been disclosed.
PF-06263726 is being developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer sponsored the Phase 1 clinical study of the compound. No partnership or licensing arrangement for this asset has been announced.
PF-06263726 is in Phase 1 clinical development. It has completed one Phase 1 trial and is not currently listed as being in any active trial. It is an investigational agent and is not approved by the FDA for any indication.
PF-06263726 has been evaluated in one completed Phase 1 trial, NCT01981681, titled a Phase 1 study to evaluate tolerability, safety, and pharmacokinetics of topical PF-06263276 in healthy subjects. The trial enrolled 47 participants in Belgium, was randomized, double blind, and placebo controlled.
The therapeutic use of PF-06263726 has not been disclosed. The compound has only been studied in a Phase 1 trial in healthy volunteers, which assessed tolerability, safety, and pharmacokinetics rather than efficacy in a patient population. No approved indication exists for this investigational small molecule.